Rijnstate
Arnhem, Gelderland, 6815 AD, Netherlands
NCT Number: NCT05057637
Rationale: Peripheral arterial disease is a severe clinical problem with an increasing prevalence, due to an ageing population. Endovascular treatment, usually using stents, is recommended for most lesions in the femoropopliteal tract. The patency of these stents is influenced by several factors, including stent sizing and stent positioning.
Current procedural planning of femoropopliteal disease is primarily based on single-plane digital subtraction angiographies (DSA). This modality provides a 2-dimensional image of the vessel lumen, which may be suboptimal for stent sizing. It can therefore be difficult to choose the optimal stent position as minor lesions may be missed. Suboptimal treatment could result in unfavourable levels of wall shear stress causing the vessel wall to be more susceptible to neo-intimal hyperplasia ultimately causing restenosis and stent failure. Intravascular optical coherence tomography (OCT) is able to visualize the arterial wall with a micrometer resolution, which could result in better stent sizing. Furthermore, OCT is able to visualize different layers in the vessel wall and identify unhealthy areas, which may lead to a more optimal stent placement as unhealthy areas can be covered completely. Moreover, OCT provides detailed patient-specific geometries necessary to develop reliable computational fluid dynamics (CFD) models that simulate blood flow in stented arteries and calculate wall shear stresses, which could predict stent patency.
Objective: To investigate in a clinical study how often the use of intravascular optical coherence tomography for femoropopliteal stenotic lesions leads to alterations in treatment planning before and after stent placement, in comparison to traditional digital subtraction angiography-based treatment planning.
Study design: Exploratory observational study. Study population: 25 patients with femoropopliteal stenotic lesions who are treated with a Supera interwoven nitinol stent or Absolute nitinol stent.
Main study parameters/endpoints: The percentage of procedures in which OCT changed the DSA-based treatment planning before and after stent placement to investigate the impact of OCT imaging on treatment planning.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Observational
Arnhem, Gelderland, 6815 AD, Netherlands
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Optical coherence tomography measurements in femoropopliteal tract
Other names: Ilumien Optis
Time frame: Immediately following the procedure
The percentage of procedures in which the OCT changed the DSA-based treatment planning before and after stent placement to investigate the impact of OCT imaging on treatment planning.
Time frame: 6-8 weeks after the procedure
The presence of artefacts will be used to determine the image quality of the CTA scan
Time frame: Immediately following the procedure
The presence of artefacts will be used to determine the image quality of the OCT scan
Time frame: Up to 2 years after the procedure
The vessel lumen in the CTA scan will be segmented to obtain a patient-specific geometry.
Time frame: Up to 2 years after the procedure
The vessel lumen in the OCT scan will be segmented to obtain a patient-specific geometry.
Time frame: Up to 2 years after the procedure
The obtained CTA-based segmentation will be compared to the OCT-based segmentation. The vessel radius along the blood vessel for both the CTA-based and OCT-based segmentation will be compared point-by-point after which the correlation beteen both segmentations will be obtained
Time frame: Up to 2 years after the procedure
Velocity streamlines are calculated using a computational fluid dynamics model based on the CTA-based vessel lumen segmentation.
Time frame: Up to 2 years after the procedure
The second parameter calculated using the CTA-based CFD simulation is the time averaged wall shear stress. This is the wall shear stress averagerd over one heartbeat.
Time frame: Up to 2 years after the procedure
Velocity streamlines are calculated using a computational fluid dynamics model based on the OCT-based vessel lumen segmentation.
Time frame: Up to 2 years after the procedure
The second parameter calculated using the OCT-based CFD simulation is the time averaged wall shear stress. This is the wall shear stress averagerd over one heartbeat.
Time frame: Up to 2 years after the procedure
Defined as the vessel diameter right after procedure minus the vessel diameter during follow-up
Time frame: Up to 2 years after the procedure
The regions with late luminal loss will be compared to regions with disturbed velocity streamlines and low time averaged wall shear stress (<0.4 Pa) calculated with the CTA-based CFD. This correlation shows how well the CTA-based CFD model can predict late luminal loss.
Time frame: Up to 2 years after the procedure
The regions with late luminal loss will be compared to regions with disturbed velocity streamlines and low time averaged wall shear stress (<0.4 Pa) calculated with the OCT-based CFD. This correlation shows how well the OCT-based CFD model can predict late luminal loss.
Rijnstate Hospital
Other
The Impact of Optical Coherence Tomography on the Decision-making Process of Endovascular Treatment of Femoropopliteal Disease
Acronym: Optimo
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04584632
Arterial Occlusive Diseases, Arteriosclerosis
Sydney, New South Wales, Australia
View Trial DetailsNCT06260488
Arterial Occlusive Diseases, Arteriosclerosis
Strasbourg, Bas-Rhin, France
View Trial DetailsNCT06082466
Cardiovascular Diseases, Claudication, Intermittent
Salzburg, Austria
View Trial DetailsNCT05312580
Angiopathy, Peripheral, Arterial Occlusive Diseases
Innsbruck, Austria
View Trial Details